Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

王蓉,束永前,刘连科,刘永彪,刘平,黄普文,殷咏梅,卢凯华
DOI: https://doi.org/10.3969/j.issn.1671-4695.2007.12.012
2007-01-01
Abstract:Objective To observe the short term efficacy and toxicity of three commonly used cisplatin-based regimens for treating patients with advanced non-small cell lung cancer(NSCLC).Methods 70 patients with advanced NSCLC diagnosed by pathologic or cytological examination were randomly enrolled into three groups: 24 patients in NP(vinorelbine combined with cisplatin) group,25 patients in GP(gemcitabine combined with cisplatin) group and 21 patients in TP(docetaxel combined with cisplatin) group,and the treatment in all patients was carried out for 21 days as a course.The response and toxicity of chemotherapy were evaluated after 2 courses.Results The overall response rates in NP group,GP group and TP group were 29.2%(7/24),40.0%(10/25) and 33.3%(7/21) respectively,and their difference was not statistically significant(P0.05).The occurrence of neutropenia and anemia was approximately same in these 3 regimens.Thrombocytopenia at grade Ⅲ﹣Ⅳ was significantly higher in the GP regimen(16%) than that of others.For the TP regimen,peripheral neurotoxicity at grade Ⅰ-Ⅱ(38.1%) was most common.Phlebitis at grade Ⅰ-Ⅱ was more frequently seen in NP regimen(14.6%) than the other two.Conclusion There was no significant difference in groups NP、GP and TP on short term efficacy.These regimens could be used as first-line chemotherapy in treatment of advanced NSCLC.The occurrence of toxicities in these regimens was different,so the choice of chemotherapy by clinicians should be based on individual conditions of patients.
What problem does this paper attempt to address?